【AEA 2016 Alumni】
DRD Biotech, R&D company based in Russia, Ulan-Ude city (Buryatia republic).

DRD develop and implements a point-of-care rapid test kits to accelerate and improve the early detection of brain damage. We have a mission to create a simple and affordable solution, requires no technical equipment to accelerate decision support in acute situations such as Stroke management and TBI.

There are two main directions in our pipeline:

• ・Diagnostic assay for assessment of Ischemic Stroke/TIA
• ・Diagnostic assay for assessment the severity of concussion.

The key element of our lateral flow immunoassays are brain biomarkers of brain damage peptides and antibodies of NMDA and AMPA glutamate receptors.

There are several areas of implementation for brain damage immunoassays:

• ・Ambulance and Emergency department (Acute Ischemic Stroke, Strove vs. no Stroke, mTBI)
• ・Rehabilitation and treatment monitoring (to monitoring efficiency of treatment of chronical ischemic events)
• ・Neurosurgery and cardiac surgeries (to avoid risk of ischemic events during and after surgical operations)
• ・Maternity and childbirth (children risk assessment of near-term ischemic events during and after childbirth especially after complicated childbirth)
• ・Screening people with pre-existing conditions such as hypertension, diabetes, artherosclerosis, smoking, alcohol intake, etc. (To accurately risk assessment and monitoring of preventive therapy)
• http://www.drdbiotech.ru/#!home/c1anm